{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:17:25Z","timestamp":1767665845148,"version":"3.29.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.gastrohep.2024.502199","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:31:12Z","timestamp":1715095872000},"page":"502199","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the clinical and economic value of sofosbuvir\/velpatasvir (SOF\/VEL) in patients with chronic hepatitis C in Spain during the last 5 years"],"prefix":"10.1016","volume":"47","author":[{"given":"Rafael","family":"Esteban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Dom\u00ednguez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Cantero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2024.502199_bib0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0175","unstructured":"Ministerio de Sanidad. Segundo Estudio de Seroprevalencia en Espa\u00f1a. 2020. Available from: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/EstudioSeroprevalencia_EnfermedadesInmunoprevenibles.pdf."},{"key":"10.1016\/j.gastrohep.2024.502199_bib0180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0190","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gastrohep.2017.11.008","article-title":"Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain","volume":"41","author":"Sicras-Mainar","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0195","first-page":"23","article-title":"Burden outcome, and comorbidities of extrahepatic manifestations in hepatitis C virus infection","volume":"12","author":"Songtanin","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0200","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/v13112249","article-title":"A review on extrahepatic manifestations of chronic hepatitis c virus infection and the impact of direct-acting antiviral therapy","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2019.04.014","article-title":"Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia","volume":"71","author":"Alavi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0210","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0215","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0220","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.gastrohep.2018.07.010","article-title":"Guidelines on treatment of hepatitis C virus infection Spanish Association for the Study of the Liver (AEEH)","volume":"41","author":"Calleja","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0225","doi-asserted-by":"crossref","unstructured":"European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2024.502199_bib0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0210-5705(20)30185-0","article-title":"Economic impact of health resource optimisation in the approach to patients with hepatitis C","volume":"42","author":"Turnes","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0235","unstructured":"World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. 2016."},{"key":"10.1016\/j.gastrohep.2024.502199_bib0240","doi-asserted-by":"crossref","first-page":"e0278544","DOI":"10.1371\/journal.pone.0278544","article-title":"Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain","volume":"17","author":"Esteban","year":"2022","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0245","unstructured":"Ministerio de Sanidad \u2013 Profesionales \u2013 Pacientes que inician tratamiento para hepatitis C cr\u00f3nica con antivirales de acci\u00f3n directa. 2023. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/publicaciones\/planOptimizacion\/tratamientoHepatitisC.htm."},{"key":"10.1016\/j.gastrohep.2024.502199_bib0250","unstructured":"Gilead Sciences. Data on file 2018\u20132019."},{"key":"10.1016\/j.gastrohep.2024.502199_bib0255","doi-asserted-by":"crossref","first-page":"e0215783","DOI":"10.1371\/journal.pone.0215783","article-title":"SVR12 rates higher than 99% after sofosbuvir\/velpatasvir combination in HCV infected patients with F0\u2013F1 fibrosis stage: a real world experience","volume":"14","author":"Mangia","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0260","unstructured":"C\u00e1lculo de variaciones del Indice de Precios de Consumo. INE. Available from: https:\/\/www.ine.es\/varipc."},{"key":"10.1016\/j.gastrohep.2024.502199_bib0265","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"A proposed guideline for economic evaluation of health technologies","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0270","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jhep.2020.07.018","article-title":"Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025","volume":"73","author":"Rodr\u00edguez-Tajes","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0275","doi-asserted-by":"crossref","first-page":"102142","DOI":"10.1016\/j.canep.2022.102142","article-title":"Prevalence and characteristics of hepatitis C virus-related hepatocellular carcinoma in a Spanish university hospital","volume":"78","author":"Canillas","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0280","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0290","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/hepr.13868","article-title":"Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis","volume":"53","author":"Tahata","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0295","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.32237","article-title":"Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain","volume":"75","author":"Politi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0300","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.18176\/resp.00012","article-title":"Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain","volume":"22","author":"Marco","year":"2020","journal-title":"Rev Esp Sanid Penit"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0310","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial","volume":"1","author":"Younossi","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0315","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","article-title":"Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection without or with compensated or decompensated cirrhosis","volume":"15","author":"Younossi","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0320","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cgh.2021.01.026","article-title":"Long-term patient-centered outcomes in cirrhotic patients with chronic hepatitis C after achieving sustained virologic response","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2024.502199_bib0325","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jhep.2020.11.042","article-title":"The global burden of cirrhosis: a review of disability-adjusted life-years lost and unmet needs","volume":"75","author":"Jepsen","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502199_bib0330","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000000336","article-title":"Labour productivity losses caused by premature death associated with hepatitis C in Spain","volume":"27","author":"Oliva-Moreno","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:43:17Z","timestamp":1732732997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570524001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0210570524001572"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502199","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the clinical and economic value of sofosbuvir\/velpatasvir (SOF\/VEL) in patients with chronic hepatitis C in Spain during the last 5 years","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502199"}}